All In MedTech

Device Trial Radar · NCT06116292

Impact of the Implementation of a Telemedicine Program on Patients Diagnosed With Asthma

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

75

Actual

Start

Jan 1, 2024

Primary completion

Jan 29, 2026

Study completion Jan 29, 2026

Sponsor

Lead sponsor
Hospital Universitari de BellvitgeAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 3, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Introduction: Asthma is one of the most common chronic respiratory diseases worldwide. Despite the extensive knowledge of the condition and available therapeutic options, severe asthmatic patients have poor disease control in 50% of cases. Objective: To assess the impact of implementing a mobile application (ESTOI) in patients diagnosed with asthma on disease control, treatment adherence, and perceived quality of life. Methodology: A 52-week randomized clinical trial involving asthma patients receiving care at a highly specialized hospital in Spain. A total of 108 patients will be included and divided into two groups. The intervention group will receive more comprehensive monitoring than usual, including access to the ESTOI application. The Asthma Control Test (ACT) questionnaire will be used as the primary assessment variable. Other variables to be studied include the Inhaler Adherence Test (TAI), the number of exacerbations, peak expiratory flow, exhaled nitric oxide examination, hospital anxiety and depression scale, asthma quality of life questionnaire, forced spirometry parameters (FVC, FEV1, and reversibility), and analytical parameters (eosinophilia and IgE).

Conditions

  • Asthma
  • Telemedicine
  • Adherence, Treatment
  • Quality of Life
  • Control

Interventions

  • The mobile application ESTOI for Asthmatic patientsDevice

    The mobile application ESTOI have various sections that can be managed and customized by the researchers to meet each patient's needs: 1. SYMPTOM CONTROL, it will record the ACT, TAI, the number of exacerbations, weight, and, depending on the case, symptom control for comorbidities. 2. RECOMMENDATIONS, it will provide patients with information needed to understand their condition, how to control it, and what to do in case of worsening symptoms. 3. YOUR TREATMENT, it will display personalized and update information about the patient's current asthma medication, including dosages and frequencies. There will be explanatory videos on how to administer the therapy and includes an action plan. 4. PEAK FLOW, the patient can record measurements using a Peak Flow Meter at home. 5. NUTRITIONAL PLAN, it will provide a daily dietary guide to enable individuals to adapt these tools and recommendations to their specific needs. 6. MESSAGING, it is a bidirectional contact area.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Asthma Control Test (ACT)Time frame: Visit 1 (week 0), visit 2 (week 26) and visit 3 (week 52)
  2. Number of exacerbationsTime frame: Visit 1 (week 0), visit 2 (week 26) and visit 3 (week 52).
  3. Peak Expiratory Flow (PEF)Time frame: Visit 1 (week 0), visit 2 (week 26) and visit 3 (week 52)

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bellvitge University Hospital

    Barcelona, Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.